HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (28) Citing Articles via Google Scholar Google Scholar Articles by Linton, H. J. Articles by Mikolajczyk, S. D. Search for Related Content PubMed PubMed Citation Articles by Linton, H. J. Articles by Mikolajczyk, S. D. Related Collections Proteomics and Protein Markers Cancer Diagnostics (since 2002)

Benign Prostate-specific Antigen (BPSA) in Serum Is Increased in Benign Prostate Disease

¹ Hybritech Incorporated, a subsidiary of Beckman Coulter, Inc., San Diego, CA 92121.

² Department of Urology/Surgery, UCLA School of Medicine, Los Angeles, CA 90095.

^aAddress correspondence to this author at: Beckman Coulter, Inc, 7330 Carroll Rd., San Diego, CA 92121-2302. Fax 858-621-4610; e-mail sdmikolajczyk{at}beckman.com.

Background: BPSA is a "benign" form of free prostate-specific antigen (PSA) that is increased in prostate transition zone tissues of men with pathologic benign prostatic hyperplasia (BPH). We developed an immunoassay to determine the concentration of BPSA in the serum of men with BPH.

Methods: The BPSA antigen was purified by HPLC, and murine monoclonal antibodies were prepared by standard methods. A fluorogenic ELISA was developed with high specificity for BPSA and no cross-reactivity with other forms of PSA.

Results: The BPSA immunoassay had a lower limit of detection of 6 ng/L and a cross-reactivity of <1% with all other clipped and nonclipped forms of PSA. The BPSA antibody was specific for the internal Lys¹⁸² cleavage site that characterizes BPSA. Biopsy-negative men with a median total PSA of 4.8 µg/L had a median of 0.22 µg/L BPSA, representing 25% of the free PSA in serum. BPSA ranged from 0% to 60% of the free PSA in serum. BPSA in a cohort of cancer serum also comprised 25% of the free PSA. Control serum from women or men without increased PSA had nondetectable BPSA.

Conclusions: BPSA is a significant percentage of the free PSA in BPH serum but not in control serum. The presence of prostate cancer does not alter the relative proportions of BPSA in sera with <10 µg/L PSA. BPSA has a wide distribution of concentrations in the serum and may provide clinical information for the study of men with BPH.

The following articles in journals at HighWire Press have cited this article:

				D. Saerens, J. Kinne, E. Bosmans, U. Wernery, S. Muyldermans, and K. Conrath Single Domain Antibodies Derived from Dromedary Lymph Node and Peripheral Blood Lymphocytes Sensing Conformational Variants of Prostate-specific Antigen J. Biol. Chem., December 10, 2004; 279(50): 51965 - 51972. [Abstract] [Full Text] [PDF]

				K. Jung, J. Reiche, A. Boehme, C. Stephan, S. A. Loening, D. Schnorr, W. Hoesel, and P. Sinha Analysis of Subforms of Free Prostate-Specific Antigen in Serum by Two-Dimensional Gel Electrophoresis: Potential to Improve Diagnosis of Prostate Cancer Clin. Chem., December 1, 2004; 50(12): 2292 - 2301. [Abstract] [Full Text] [PDF]

				P. Wu, L. Zhu, U.-H. Stenman, and J. Leinonen Immunopeptidometric Assay for Enzymatically Active Prostate-Specific Antigen Clin. Chem., January 1, 2004; 50(1): 125 - 129. [Abstract] [Full Text] [PDF]